Clinical application of 5alpha-reductase inhibitors
- PMID: 11314752
- DOI: 10.1007/BF03343844
Clinical application of 5alpha-reductase inhibitors
Abstract
The inhibitors of 5alpha-reductase isoenzymes (1 and 2) can be schematically divided in three groups according they substrate specificity: a) pure or preferential inhibitor of 5alpha-reductase 1; b) pure or preferential inhibitor of 5alpha-reductase 2; c) dual inhibitors. Despite the fact that several steroidal and non-steroidal inhibitors have been synthesized and experimented in pharmacological models, only finasteride has been extensively used for clinical purposes. The largest application of finasteride in man has been human benign prostative hyperplasia (BPH). In addition, finasteride has been recently used for treatment of male baldness with a 50% of objective response. In women, finasteride has been used in some control trials for treatment of hirsutism with an objective favorable response. In conclusion, finasteride appears be useful for BPH, baldness and hirsutism (with caution) treatment. On the basis of experimental observations on distribution of 1 and 2 isoenzymes in human skin, scalp and prostate, the dual inhibitors should be more indicated for treatment of BPH and baldness. Similarly, the dual inhibitors seem indicated in attempting to prevent prostatic cancer. The pure 5alpha-reductase 1 inhibitors seem the ideal drugs for treatment of acne and hirsutism.
Similar articles
-
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.Eur Urol. 2000 Apr;37(4):367-80. doi: 10.1159/000020181. Eur Urol. 2000. PMID: 10765065 Review.
-
[Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].Urologe A. 2002 Sep;41(5):412-24. doi: 10.1007/s00120-002-0230-2. Urologe A. 2002. PMID: 12426858 Review. German.
-
Prostatic expression of human 5alpha-reductase type 2 during finasteride therapy: a randomized, double-blind, placebo-controlled study.World J Urol. 2000 Dec;18(6):406-10. doi: 10.1007/s003450000159. World J Urol. 2000. PMID: 11204259 Clinical Trial.
-
Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.Life Sci. 2002 May 31;71(2):115-26. doi: 10.1016/s0024-3205(02)01627-2. Life Sci. 2002. PMID: 12031682
-
Finasteride: a clinical review.Biomed Pharmacother. 1995;49(7-8):319-24. doi: 10.1016/0753-3322(96)82658-8. Biomed Pharmacother. 1995. PMID: 8562856 Review.
Cited by
-
Evolution, classification, structure, and functional diversification of steroid 5α-reductase family in eukaryotes.Heliyon. 2024 Jul 8;10(14):e34322. doi: 10.1016/j.heliyon.2024.e34322. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39108866 Free PMC article. Review.
-
Allopregnanolone: The missing link to explain the effects of stress on tic exacerbation?J Neuroendocrinol. 2022 Feb;34(2):e13022. doi: 10.1111/jne.13022. Epub 2021 Aug 22. J Neuroendocrinol. 2022. PMID: 34423500 Free PMC article. Review.
-
Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism.Nat Commun. 2021 Jan 19;12(1):449. doi: 10.1038/s41467-020-20675-2. Nat Commun. 2021. PMID: 33469028 Free PMC article.
-
Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia.Front Pharmacol. 2020 May 8;11:658. doi: 10.3389/fphar.2020.00658. eCollection 2020. Front Pharmacol. 2020. PMID: 32457631 Free PMC article. Review.
-
Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride.Clin Drug Investig. 2019 Jan;39(1):97-102. doi: 10.1007/s40261-018-0720-7. Clin Drug Investig. 2019. PMID: 30367429
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
